Gyre Therapeutics, Inc. Common Stock GYRE
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-06T21:48:02.804Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T21:00:00.11901288Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-06T21:46:02.896708+00:00
Gyre Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | 5.33 | 540.5% | 37.1% | |||
| 40Δ | 5.67 | 504.7% | 32.8% | |||
| 45Δ | 6.01 | 468.9% | 28.5% | |||
| 50Δ | 6.35 | 433.1% | 24.2% | |||
| 55Δ | 13.34 | 800.0% | 220.2% | 6.69 | 397.2% | 19.9% |
| 60Δ | 10.89 | 798.0% | 168.7% | 7.03 | 361.4% | 15.6% |
| 65Δ | 7.07 | 681.3% | 88.5% | 7.37 | 325.6% | 11.3% |
| 70Δ | 9.42 | 380.5% | 9.7% | |||
| 75Δ | 14.96 | 502.3% | 9.7% | |||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.33
- IV
- 540.5%
- B/E move
- 37.1%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.67
- IV
- 504.7%
- B/E move
- 32.8%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.01
- IV
- 468.9%
- B/E move
- 28.5%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.35
- IV
- 433.1%
- B/E move
- 24.2%
55Δ
- Pseudo strike
- 13.34
- IV
- 800.0%
- B/E move
- 220.2%
- Pseudo strike
- 6.69
- IV
- 397.2%
- B/E move
- 19.9%
60Δ
- Pseudo strike
- 10.89
- IV
- 798.0%
- B/E move
- 168.7%
- Pseudo strike
- 7.03
- IV
- 361.4%
- B/E move
- 15.6%
65Δ
- Pseudo strike
- 7.07
- IV
- 681.3%
- B/E move
- 88.5%
- Pseudo strike
- 7.37
- IV
- 325.6%
- B/E move
- 11.3%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.42
- IV
- 380.5%
- B/E move
- 9.7%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 14.96
- IV
- 502.3%
- B/E move
- 9.7%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
HALO
Description unavailable
More →HELP
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health…
More →HOWL
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapies designed to boost the body's immune system for the treatment of cancer. The company is headquartered…
More →HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is…
More →HUMA
Humacyte Inc (HUMA) is a groundbreaking biotechnology firm at the forefront of vascular and regenerative medicine, specializing in the development of human acellular vessels…
More →IBRX
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.
More →